The Journal of Tissue Viability is the official publication of the Tissue Viability Society and is a quarterly journal concerned with all aspects of the occurrence and treatment of wounds, including patient care, pain, nutrition, wound healing, research, prevention, mobility, social problems and management.
The Journal particularly encourages papers covering skin and skin wounds but will consider articles that discuss injury in any tissue. Articles that stress the multi-professional nature of tissue viability are especially welcome. We seek to encourage new authors as well as well-established contributors to the field - one aim of the journal is to enable all participants in tissue viability to share information with colleagues.
Editorial policy
The originality of content of papers submitted and the quality of the work on which they are based is the prime consideration of the Editor. The paper should deal with original material, neither previously published nor being considered for publication elsewhere, except in special circumstances agreed with the Editor. All papers are sent for peer review by at least two independent reviewers and are judged on their accuracy, content, organisation, style, contribution to tissue viability and appearance, The final decision regarding publication is made by the Editor and will be communicated to authors usually within 8-10 weeks after submission.
The Journal of Tissue Viability welcomes the following articles and operates a word limit as follows:
Clinical studies (1500-3000 words)
Basic research studies (1500-3000 words)
Case reports (500-1500 words)
Reviews of clinical or scientific aspects of tissue viability (1500-4000 words)
Guest editorials
Letters to the Editor (200-400 words)
Guide for Authors
These guidelines generally follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" The complete document appears at http://www.icmje.org
Submission of papers
Authors are requested to submit their original manuscript and figures online via http://ees.elsevier.com/jtv which is the Elsevier web-based submission and peer-review system. You will find full instructions located on this site - a Guide for Authors and a Guide for Online Submission. Please follow these guidelines to prepare and upload your article.
Once the manuscript has been uploaded, our system automatically generates an electronic pdf proof, which is then used for reviewing. All correspondence, including notification of the Editor's decision and requests for revisions, will be managed via this system. Authors may also track the progress of their paper using this system to final decision.
If you have any problems submitting your paper through this system, please contact the Editorial Office on: e-mail: jtv@elsevier.com; tel: +44 (0) 1392 285857; fax: +44 (0) 1392 425370.
Accepted Manuscripts Copyright Information
Upon acceptance of an article, authors will be asked to sign a 'Journal Publishing Agreement' (for more information on this and copyright see http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail (or letter) will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions).
If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.
Your manuscript should be submitted together with a covering letter which should be signed by the corresponding author on behalf of all authors and should include:
A statement that all authors have made substantial contributions to all of the following:
(1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data,
(2) drafting the article or revising it critically for important intellectual content,
(3) final approval of the version to be submitted.
Acknowledgements
All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or is the chair of the department who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.
* A statement that the manuscript, including related data, figures and tables has not been previously published and that the manuscript is not under consideration elsewhere.
* The names and contact addresses (including e-mail) of 2 potential reviewers that have not been involved in the design, performance and discussion of the data and are not a co-worker. These may or may not be used at the Editor's discretion. You may also mention persons who you would prefer not to review your paper.
Conflict of interest
At the end of the text, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there is no conflict of interest this should also be stated.
Role of the funding source
All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Please see http://www.elsevier.com/funding
Ethics
Work on human beings that is submitted to Journal of Tissue Viability should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines. Patients' and volunteers' names, initials, and hospital numbers should not be used.
Randomised controlled trials
All randomised controlled trials submitted for publication in Journal of Tissue Viability should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. Journal of Tissue Viability has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at www.icmje.org
Patient Consent
Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper.
Patients have a right to privacy. Therefore identifying information, including patient images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.
Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.
If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission. For further information see http://www.elsevier.com/patientphotographs.
Types of Submission
Clinical and Scientific Research
Papers should adhere to the word count listed above and contain the following:
Authors full names, academic and professional affiliations and complete addresses should be included on a separate title page. The name and address of the author to whom reprint requests are to be sent should be stated on the title page. Abstract and Key words: A summary of 200- 250 words is mandatory. This should be a structured abstract listing the aim of the study, the materials and methods, the results and the Conclusion. A list of 3 -8 key words, which convey the meaning of the paper should be provided and submitted with the manuscript. In the event that key words are not supplied editorial discretion will be exercised in introducing appropriate key words.
Papers should be concisely written and generally they should be clearly divided into numbered sections, 1. Introduction, 2. Material and Methods, 3. Results, 4. Discussion, 5. Conclusions, 6. Conflict of Interest, 7. Acknowledgments, 8. References, 9. Legends to figures etc.
Editorials
The editorial in each issue of the Journal is typically written by a guest editor rather than the Editor of the Journal. Typically guest editors will be invited to submit by the Editor and will be asked to provide 800-1000 words upon a topic of debate or controversy. Each editorial reflects the views of its author and may be supported by no more than five references. While the majority of editorials are commissioned, please do not hesitate to submit an outline idea or contact the Editor to discuss your proposal.
Case reports
Reports of either an individual or a series of case histories are acceptable if they are used to raise awareness of a particular aspect of tissue viability rather than to simply describe what happened to a patient(s) over a period of time. Authors should carefully consider what general points they would wish readers to take from their case report before starting to write.
Reviews
Structured or systematic reviews of any topic related to tissue viability are welcomed. Please contact the Editor to discuss your proposed topic before starting to prepare the manuscript to establish whether the topic is likely to be relevant to the Journal. Clear evidence is required within the manuscript that a systematic approach to gathering the literature cited in the review was followed.
Letters
Letters related to any topic covered in the previous issue of the Journal of Tissue Viability are welcomed, as are all letters relevant to any issue in tissue viability. We encourage the submission of letters as a strong vehicle for provoking discussion and debate within the Journal. Letters will not be subject to peer review but are published at the discretion of the Editor.
Language
Journal of Tissue Viability is an international journal and it is the aim of the Editor to produce papers in clear and concise language. Generic names should be used for all drugs.
Statistical treatment of results will be expected wherever this is feasible.
References should be in superscript in the order of citation in which they are first mentioned in the text (and placed after the full stop if this is the end of the sentence) and listed in numerical sequence on a separate sheet. References cited only in tables or figure legends should be numbered in accordance with the sequences established by the first identification in the text of the particular figure or table. List all authors when there are six or less: when there are seven or more, list the first three, then "et al". The titles of journals should be abbreviated according to the style used in Index Medicus. The list of journals can be found at http://www.nlm.nih.gov/tsd/serials/terms_cond.html.
The following are sample references:
Articles in Journals
1. Ross P, Nolan J, Hill E, Dawson J, Whimster F. The use of AEDs by police officers in the City of London. Resuscitation 2001;50:141-6.
2. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.
Books
3. Armitage P. Statistical methods in medical research. London: Blackwell Scientific Publications, 1971. Chapters
4. Phillips SJ, Whisnant JP Hypertension and stroke. In Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. P465p.465-78.
Numbered references to personal communications, unpublished data or manuscripts either "in preparation" or "submitted for publication" are unacceptable. If essential, such material may be incorporated at the appropriate place in the text.
Illustrations must be in a form and condition suitable for reproduction. The illustration should bear the manuscript titles and be numbered in Arabic numerals according to the sequence of their appearance in the text, where they should be referred to as Fig. 1, Fig. 2, etc. Line-drawings should be drawn at least twice the size of which they are intended to appear finally. Lettering should be clear and of adequate size to be legible after reduction. The degree of reduction will be determined by the publisher, but in general it should be assumed that the same degree of reduction will be applied to all figures in the same paper. All figures supplied in colour will be published in colour electronically. If print colour reproduction is required, this will be charged to the author(s). Each illustration must have a legend. These should be typed with double-spacing on a separate page and begin with the number of the illustration they refer to.
Tables of numerical data should each be typed (also with double-spacing) on a separate page, numbered in sequence in Arabic numerals (Table 1, 2, etc.) provided with a heading and a legend, and referred to the text as Table 1, Table 2, etc.
Authors in Japan please note: Upon request, Elsevier Japan will provide authors with a list of people who can check and improve the English of their paper (before submission). Please contact our Tokyo office: Elsevier Japan, 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106-0044; Japan; Tel. (+81) 3-5561-5032; Fax: (+81)3-5561-5045; E-mail: info@elsevier.co.jp English language help service: Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (before submission). please visit http://www.elsevier.com/languagepolishing for more information.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors who publish in Elsevier journals to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.
Change to Authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.
Authors' rights
As an author you (or your employer or institution) retain certain rights; for details you are referred to: http://www.elsevier.com/authors/author-rights-and-responsibilities.
Author Enquiries
The facility to track accepted articles and set up e-mail alerts to inform you when an article's status changes can be found at: http://authors.elsevier.com/TrackPaper.html. There is also information on artwork guidelines, copyright information, and answers to frequently asked questions.
Proofs
One set of page proofs in PDF format will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post). Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post.
Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.
All questions relating to proofs should be directed to: Elsevier Exeter Ltd., E mail JTV@elsevier.com
Reprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail or, alternatively, 25 free paper offprints. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Additional paper offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.
Open access
This journal offers you the option of making your article freely available to all via the ScienceDirect platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements are available at http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this option, should complete and submit the order form (available at http://www.elsevier.com/locate/openaccessform.pdf). Whatever access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article on your own website. More information can be found here: http://www.elsevier.com/authorsrights.
刊名字顺( Alphabetical List of Journals):
返回页首 